Sam M, Nick B,Tim M I. New Antibody Drug Treatments for Lymphoma[J]. Expert Opinion on Biological Therapy, 2011, 11(5): 623-640.
[2]
Ferrer L, Bodet-M C. Three Methods Assessing Red Narrow Dosimetry in Lymphoma Patients Treated with Radioimmunotherapy[J]. Cancer, 2010, 116(4 Suppl): 1093-1100.
[3]
Shin I S, Lee S M, Kim H S,et al. Effect of Chelator Conjugation Level and Injection Dose on Tumor and Organ Uptake of 111In-Labeled MORAb-009, an Anti-Mesothelin Antibody[J]. Nuclear medicine and biology, 2011, 38(8): 1119-1127.
[4]
Angel C, Gerardo L, Iván G, et al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188Re in adult recurrent high-grade glioma[J]. Cancer Biology & Therapy,2008,7(3): 1-6.
[5]
Nigora R, Vladimir L, Dauranbek A, et al. Effectiveness of bone metastases treatment by 153Sm oxabifore in combination with monoclonal antibody denosumab (Xgeva): first experience[J]. World Journal of Nuclear Medicine, 2013, 12(1): 19-23.
[6]
Edalat R, Amir R J, Hassan Y,et al. A Comparative study of preliminary nary dosimetry for human based on distribution data in rats with 111In, 90Y, 153Sm, and 177Lu labeled rituximab[J]. Nuclear Technology & Radiation Protetion, 2012, 27(2): 144-151.
[7]
ClinicalTrials. Phase 3 Trial of 90Y-Clivatuzumab tetraxetan & gemcitabine vs placebo & gemcitabine in metastatic pancreatic cancer[C]. gov-Identifier: NCT01956812, 2014, 9.
[8]
Ylva A,Ann C S,Hans L, et al. Biodistribution of 211At-labeled humanized monoclonal antibody A33[J]. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22(4): 480-487.
[9]
Zalutsky M R, Reardon D A, Akabani G, et al. Clinical experience with α-Particle-emitting 211At: treatment of recurrent brain tumor patients with 211At-Labeled chimeric antitenascin Monoclonal Antibody 81C6[J]. Journal of Nuclear Medicine, 2008, 49(1): 30-38.
[10]
Sophie E E, Tom B, Erika E, et al. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb[J]. EJNMMI Research, 2013, 3(1): 23-31.
[11]
Susan E A, Anders , Bo J, et al. In vivo evaluation of the radiolabeled ICAM-1 monoclonal antibody R6.5 in a prostate cancer mouse model[J]. Journal of Nuclear Medicine, 2014, 55 (Supplement 1): 1416.
[12]
Scott T T, Matthew I M, Michael M, et al. Phase Ⅱ trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers[J]. Clinical Cancer Research, 2013, 19(18): 5182-5191.
[13]
Alexander B S, Otto C B, Ingrid M E D, et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled Anti-Carbonic anhydrase Ⅸ-monoclonal antibody girentuximab in patients with Advanced renal cell carcinoma[J]. European -Urology, 2013,64(1): 478-485.
[14]
Moumita M. Probable nuclear reactions to produce proton rich rhenium radionuclides[J]. Journal of Radioanalytical and Nuclear Chemistry, 2011, 290(1): 11-16.
[15]
Hong S,George S. Therapeuticradionuclides in nuclear medicine:current and future prospects[J]. Current Drug Delivery, 2011, 8(1), 26-44.
[16]
Morgenstern A, Bruchertseifer F, Apostolidis C. targeted alpha therapy with 213Bi[J]. Current Radiopharmaceuticals, 2011,4(4): 295-305.
[17]
Rey A M. Radiometal complexes in molecular imaging and therapy[J]. Current Medicinal Chemistry, 2010, 17(11):3673-3683.
[18]
Brechbiel M W，Gansow O A. Synthesis of 1-(p-1sothiocyanatobenzyI) derivatives of DTPA and EDTA. antibody labeling and tumor-imaging studies[J]. Inorganic Chemistry, 1986, 25(16): 2 772-2781.
[19]
Geoffrey L R, Kwamena E B, Lanea M M K ,et al. Pre-Clinical assessment of 177Lu-Labeled trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal-disease[J]. Pharmaceuticals, 2012, 5(1): 1-15.
[20]
Asti M, Tegoni M, Farioli D, et al. Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions[J]. Nuclear Medicine and Biology, 2012, 39(4): 509-517.
[21]
Camera L, Kinuya S, Garmestani K,et al. Comparative biodistribution of indium and yttrium-labeled B3 monoclonal antibody conjugated to either 1B4M-DTPA or 2B-DOTA[J]. European Journal of Nuclear Medicine, 1994, 21(7): 640-646.
[22]
Woods M, Kovacs Z, Kiraly R,et al. Solution dynamics and stability of lanthanide (Ⅲ) (S)-2-(p-Nitrobenzyl) DOTA complexes[J]. Inorganic Chemistry, 2004, 43(9): 2845-2851.
[23]
Linda M, Zhongmin W, Rune N. Determining maximal tolerable dose of the monoclonal antibody BR96 Labeled with 90Y or 177Lu in Rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy[J]. Clinical Cancer Research, 2005, 11(19 Pt 2): 7104s-7108s.
[24]
Paola F A, Gustavo C, Marcos R T,et al. [177Lu]DOTA-anti-CD20:Labeling and preclinical studies[J]. Applied Radiation and Isotopes, 2011, 69(7): 924-928.
[25]
Parul T, Suhas S, Madhav P Y,et al. An approach for conjugation of 177Lu-DOTA-SCN Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients[J]. The Indian Journal of Medical Research, 2014, 139(4): 544-554.
[26]
Samira R, Hossein R. Toxicity of trastuzumablabeled177Lu onMCF7and SKBr3celllines[J]. Applied Radiation and Isotopes, 2010, 68 (10): 1964-1966.
[27]
Vera D R, Eigner S, Henke K E,et al. Preparation and preclinical evaluation of177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors[J]. Nuclear Medicine and Biology, 2012, 39(1): 3-13.
[28]
Colnot DR, Quak JJ, Roos JC,et al. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck[J]. Journal of Nuclear Medicine, 2000, 41(12): 1999-2010.
[29]
Pontus K E B, Ernst J P, Jan C R, et al. Phase I therapy study with186Re-labeled humanized monoclonal antibody BIWA 4(Bivatuzumab) in patients with head and neck squamous cell carcinoma[J]. Clinical Cancer Research, 2003, 9(9): 3961s-3972s.
[30]
Ernst J P, John M M R, Wim J G O, et al. Final results of a phase I radioimmunotherapy trial using186Re-Epratuzumab for the treatment of patients with Non-Hodgkin’s lymphoma[J]. Clinical Cancer Research, 2003, 9(9): 3995s-4002s.
[31]
Li G P, Huang K, Zhang H. Efficacy of 188Re-herceptin radioimmunotherapy in nude mouse model of nasopharyngeal carcinoma[J]. Journal of Southern Medical University, 2006, 26(4): 459-462.
[32]
Gholipour N, Vakili A, Jalilian AR,et al. Optimization of 90Y-antiCD20 preparation for radioimmunotherapy[J]. Journal of Cancer Research & Therapeutics, 2013, 9(2): 199-204.
[33]
Vaes M, Bron D, Vugts D J, et al. Safety and efficacy of radioimmunotherapy with 90Y-rituximab in Patients with Relapsed CD20+ B cell lymphoma: A feasibility study[J]. Journal of Cancer Science & Therapy, 2012, 4(12): 394-400.
[34]
Ariandokht V, Amir R J, Kamal Y, et al. Preparation and quality control and biodistribution studies of [90Y]-DOTA-cetuximab for radioimmunotherapy[J]. Journal of Radioanalytical and Nuclear Chemistry, 2013, 296(3): 1287-1294.
[35]
Thompson S, Ballard B, Jiang Z,et al. 166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel[J]. Nuclear Medicine and Biology, 2014, 41(3): 276-281.
[36]
Dadwal M, Kang C S, Song H A, et al. Synthesis and evaluation of a bifunctional chelate for development of Bi(Ⅲ)-labeled radioimmunoconjugates[J]. Bioorganic & Medicinal Chemistry, 2011, 21(24): 7513-7515.
[37]
Kang C S, Song H A, Milenic D E,et al. Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies[J]. Nuclear Medicine and Biology, 2013, 40(5): 600-605.
[38]
Vaidyanathan G, Zalutsky R M. Applications of 211At and 223Ra in targeted alpha-Particle radio therapy[J]. Current Radiopharmaceuticals, 2011, 4(4): 283-294.
